Hoppa till innehål
banner-mesenkia-8

New preprint reveals a signaling pathway essential to glioblastoma

Inhibition of HVEM suppresses invasion and growth of mesenchymal glioblastoma

A new preprint from our scientific founders — Ryo Tanabe, Bengt Westermark, Carl-Henrik Heldin and Kohei Miyazono — sheds further light on the role of HVEM (TNFRSF14) in glioblastoma.

  • BioRxiv_logo

The study shows that HVEM is differentially expressed in mesenchymal glioblastoma-initiating cells and drives tumour progression. The researchers found that the ligand APRIL, secreted by these cells, binds HVEM and activates NF-κB signalling — and that inhibiting HVEM suppresses both the growth and the invasive spread of mesenchymal glioblastoma.

These findings reinforce the scientific rationale behind Mesenkia’s first-in-class approach to HVEM-targeted therapy.

Read the full preprint on bioRxiv

More news

See all news

BioArctic and Mesenkia enter oncology research collaboration

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and Mesenkia Therapeutics announced today that the companies have signed a research collaboration ...

New Preclinical Findings Identify HVEM as a Promising Target in Aggressive Glioblastoma

Researchers have identified HVEM as a promising therapeutic target in mesenchymal glioblastoma...

Kohei Miyazono new member at the royal Swedish academy of science.

Kohei Miyazono has been elected as a new member to the Academy’s class for medical sciences at the royal ...

Cookieconcent

The website uses necessary cookies to ensure the website functions properly. You can also choose to consent to cookies for statistical purposes.